Johnson & Johnson reports Phase 2b results for JNJ-4804, a dual IL-23 and TNF-α co-antibody, showing improved remission rates in refractory ulcerative colitis and Crohn’s disease.
Written by: Farha Farheen, Pharm D
Reviewed By: Pharmacally Editorial Team
Johnson & Johnson has announced promising Phase 2b results for its investigational co-antibody therapy, JNJ-4804, in patients with moderately to severely active inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD) who are refractory to prior systemic therapies.
The therapy demonstrated clinically meaningful improvements in both clinical and endoscopic outcomes, particularly among patients with highly refractory disease who have failed prior treatments.
The efficacy and safety of JNJ-4804 were evaluated in the Phase 2b DUET-CD (NCT05242471) and DUET-UC (NCT05242484) trials, randomized studies in patients with Crohn’s disease and ulcerative colitis, respectively, who had an inadequate response to two or more classes of systemic or advanced therapies.
Results showed that JNJ-4804 achieved higher observed rates of clinical remission and endoscopic response compared with active comparator arms, including Golimumab and Guselkumab monotherapies, in these populations.
In Crohn’s disease, JNJ-4804 demonstrated a clinical remission rate of approximately 50.8% at Week 48 in the overall DUET-CD population, compared with lower rates observed in the comparator arms. In UC, the therapy achieved a remission rate of about 41.0% at Week 48, again higher than the respective comparator groups.
Importantly, JNJ-4804 showed meaningful benefits even in a subpopulation of patients who had failed multiple prior biologic treatments, supporting its potential role in highly refractory IBD.
The safety profile of JNJ-4804 was consistent with the known effects of IL-23 and TNF-α inhibition, with no new safety signals identified, and the therapy was generally well tolerated.
Co-antibody approaches represent an emerging strategy in immunology, enabling simultaneous targeting of multiple disease-relevant pathways within a single therapeutic agent.
JNJ-4804 is a novel, fixed-dose co-antibody designed to simultaneously target interleukin-23 (IL-23) and tumor necrosis factor-α (TNF-α), two key inflammatory pathways in the pathogenesis of IBD. By dual inhibition of these cytokines, the therapy is designed to provide improved disease control compared to existing single-target biologics.
IBD is a chronic, immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract. Patients with moderate to severe disease often experience symptoms such as abdominal pain, diarrhea, fatigue, and weight loss.
Despite multiple biologic options, a substantial proportion of patients fail to achieve or maintain remission, underscoring a major unmet medical need, particularly in refractory cases.
These findings indicate that JNJ-4804 has the potential to improve treatment outcomes in inflammatory bowel disease, particularly for patients with limited therapeutic options. Johnson & Johnson plans to advance the therapy into Phase 3 trials to further evaluate its efficacy and safety in larger patient populations.
Overall, the development of JNJ-4804 represents a meaningful step forward in the management of refractory inflammatory bowel disease. By offering dual-targeted immunomodulation, this therapy may enhance remission rates, reduce disease burden, and improve quality of life for patients with UC and CD.
References
About the Writer
Farha Farheen, Pharm.D, is a pharmacy professional with a strong interest in pharmacovigilance and clinical research. She has completed her Doctor of Pharmacy (Pharm.D) along with her internship as a Clinical Pharmacist. She has hands-on experience in adverse drug reaction (ADR) reporting, safety data documentation, and pharmacovigilance workflows, and is proficient in using VigiFlow. She is also a patent holder for an antibacterial formulation enriched with bioactive substances, granted by the German Patent and Trademark Office.